BioVie Inc. (NASDAQ:BIVI) Short Interest Update

BioVie Inc. (NASDAQ:BIVI) saw a large drop in short interest during the month of February. As of February 27th, there was short interest totaling 141,788 shares, a drop of 20.3% from the February 12th total of 177,894 shares. Based on an average trading volume of 102,551 shares, the days-to-cover ratio is currently 1.4 days. Approximately 1.9% of the shares of the company are short sold. Approximately 1.9% of the shares of the company are short sold. Based on an average trading volume of 102,551 shares, the days-to-cover ratio is currently 1.4 days.

BioVie Price Performance

Shares of BIVI stock opened at $1.41 on Friday. The stock has a market capitalization of $10.64 million, a price-to-earnings ratio of -0.43 and a beta of 0.51. The company’s fifty day simple moving average is $1.26 and its two-hundred day simple moving average is $1.51. BioVie has a 1 year low of $1.06 and a 1 year high of $13.20.

BioVie (NASDAQ:BIVI) last posted its quarterly earnings results on Friday, February 6th. The company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.04.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new stake in shares of BioVie during the fourth quarter valued at about $25,000. Two Sigma Investments LP bought a new position in shares of BioVie in the third quarter valued at approximately $62,000. Squarepoint Ops LLC bought a new position in shares of BioVie in the third quarter valued at approximately $63,000. NewEdge Advisors LLC grew its stake in BioVie by 283.7% during the first quarter. NewEdge Advisors LLC now owns 54,100 shares of the company’s stock valued at $53,000 after acquiring an additional 40,000 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in BioVie during the second quarter valued at approximately $57,000. Institutional investors own 4.59% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioVie in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

BioVie Company Profile

BioVie Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.

The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease.